134 related articles for article (PubMed ID: 25552400)
1. Pharmacokinetics of neamine in rats and anti-cervical cancer activity in vitro and in vivo.
Liu Y; Zhang X; An S; Wu Y; Hu G; Wu Y
Cancer Chemother Pharmacol; 2015 Mar; 75(3):465-74. PubMed ID: 25552400
[TBL] [Abstract][Full Text] [Related]
2. Neamine inhibits growth of pancreatic cancer cells in vitro and in vivo.
Liu YP; Wu YL; Zhang XY; Hu GF; Wu YX
J Huazhong Univ Sci Technolog Med Sci; 2016 Feb; 36(1):82-87. PubMed ID: 26838745
[TBL] [Abstract][Full Text] [Related]
3. Neamine inhibits xenografic human tumor growth and angiogenesis in athymic mice.
Hirukawa S; Olson KA; Tsuji T; Hu GF
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8745-52. PubMed ID: 16361562
[TBL] [Abstract][Full Text] [Related]
4. Sub-chronic 90-day toxicity of neamine in SD rats and its anti-liver cancer activity in vitro and in vivo.
Wu Y; Feng Y; Li Y; Xu Y; Shi N; Hu GF; Wu Y
Toxicol Appl Pharmacol; 2017 Jan; 315():50-59. PubMed ID: 27940282
[TBL] [Abstract][Full Text] [Related]
5. Neamine inhibits oral cancer progression by suppressing angiogenin-mediated angiogenesis and cancer cell proliferation.
Kishimoto K; Yoshida S; Ibaragi S; Yoshioka N; Hu GF; Sasaki A
Anticancer Res; 2014 May; 34(5):2113-21. PubMed ID: 24778013
[TBL] [Abstract][Full Text] [Related]
6. Neamine inhibits prostate cancer growth by suppressing angiogenin-mediated rRNA transcription.
Ibaragi S; Yoshioka N; Li S; Hu MG; Hirukawa S; Sadow PM; Hu GF
Clin Cancer Res; 2009 Mar; 15(6):1981-8. PubMed ID: 19276260
[TBL] [Abstract][Full Text] [Related]
7. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
Ferguson D; Rodriguez LE; Palma JP; Refici M; Jarvis K; O'Connor J; Sullivan GM; Frost D; Marsh K; Bauch J; Zhang H; Lin NH; Rosenberg S; Sham HL; Joseph IB
Clin Cancer Res; 2005 Apr; 11(8):3045-54. PubMed ID: 15837760
[TBL] [Abstract][Full Text] [Related]
9. Kaposi's sarcoma-associated herpesvirus-positive primary effusion lymphoma tumor formation in NOD/SCID mice is inhibited by neomycin and neamine blocking angiogenin's nuclear translocation.
Bottero V; Sadagopan S; Johnson KE; Dutta S; Veettil MV; Chandran B
J Virol; 2013 Nov; 87(21):11806-20. PubMed ID: 23986578
[TBL] [Abstract][Full Text] [Related]
10. Phloretin suppresses metastasis by targeting protease and inhibits cancer stemness and angiogenesis in human cervical cancer cells.
Hsiao YH; Hsieh MJ; Yang SF; Chen SP; Tsai WC; Chen PN
Phytomedicine; 2019 Sep; 62():152964. PubMed ID: 31153059
[TBL] [Abstract][Full Text] [Related]
11. Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells.
Peng Y; Li L; Huang M; Duan C; Zhang L; Chen J
Cell Signal; 2014 Dec; 26(12):2782-92. PubMed ID: 25193113
[TBL] [Abstract][Full Text] [Related]
12. The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth.
Ruggeri BA; Robinson C; Angeles T; Wilkinson J; Clapper ML
Clin Cancer Res; 2002 Jan; 8(1):267-74. PubMed ID: 11801568
[TBL] [Abstract][Full Text] [Related]
13. Anti-angiogenic quassinoid-rich fraction from Eurycoma longifolia modulates endothelial cell function.
Al-Salahi OS; Kit-Lam C; Majid AM; Al-Suede FS; Mohammed Saghir SA; Abdullah WZ; Ahamed MB; Yusoff NM
Microvasc Res; 2013 Nov; 90():30-9. PubMed ID: 23899415
[TBL] [Abstract][Full Text] [Related]
14. Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.
Liu YR; Guan YY; Luan X; Lu Q; Wang C; Liu HJ; Gao YG; Yang SC; Dong X; Chen HZ; Fang C
Biomaterials; 2015 Feb; 42():161-71. PubMed ID: 25542804
[TBL] [Abstract][Full Text] [Related]
15. The synthetic flavonoid WYC02-9 inhibits cervical cancer cell migration/invasion and angiogenesis via MAPK14 signaling.
Chen YJ; Cheng YJ; Hung AC; Wu YC; Hou MF; Tyan YC; Yuan SS
Gynecol Oncol; 2013 Dec; 131(3):734-43. PubMed ID: 24145114
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of Paris polyphylla saponin II inducing autophagic to inhibit angiogenesis of cervical cancer.
Cheng H; Long J; Su J; Chu J; Wang M; Li Q
Naunyn Schmiedebergs Arch Pharmacol; 2024 May; 397(5):3179-3194. PubMed ID: 37906274
[TBL] [Abstract][Full Text] [Related]
17. Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.
Li X; Wang X; Ye H; Peng A; Chen L
Cancer Chemother Pharmacol; 2012 Sep; 70(3):425-37. PubMed ID: 22814678
[TBL] [Abstract][Full Text] [Related]
18. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
[TBL] [Abstract][Full Text] [Related]
19. Diallyl trisulfide inhibits migration, invasion and angiogenesis of human colon cancer HT-29 cells and umbilical vein endothelial cells, and suppresses murine xenograft tumour growth.
Lai KC; Hsu SC; Yang JS; Yu CC; Lein JC; Chung JG
J Cell Mol Med; 2015 Feb; 19(2):474-84. PubMed ID: 25403643
[TBL] [Abstract][Full Text] [Related]
20. Growth inhibition of cervix carcinoma cells in vivo by endothelin A receptor blockade.
Bagnato A; Cirilli A; Salani D; Simeone P; Muller A; Nicotra MR; Natali PG; Venuti A
Cancer Res; 2002 Nov; 62(22):6381-4. PubMed ID: 12438219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
